S Zhang1, I A Shiels, J S Ambler, S M Taylor. 1. Department of Physiology and Pharmacology, University of Queensland, Brisbane, Australia. zhang@plpk.uq.oz.au
Abstract
PURPOSE: Pirfenidone is a novel anti-fibrotic drug that has been shown to inhibit fibroblast growth and collagen synthesis induced by transforming growth factor (TGF)-beta1. In the present study we investigated the ability of pirfenidone to moderate fibronectin synthesis by cultured human retinal pigment epithelial (RPE) cells maintained in media containing 1% foetal bovine serum when stimulated with TGF-beta1. METHODS: Primary human RPE cultures were used. Treatments included TGF-beta1, pirfenidone and pirfenidone with TGF-beta1. After 72 h treatments, cell growth was determined by cell counting and fibronectin was measured by ELISA. RESULTS: Transforming growth factor-beta1 (1-10 ng/mL) increased the production of soluble fibronectin, while pirfenidone (300 micromol/L) significantly reduced the TGF-beta1-induced synthesis of fibronectin. Pirfenidone alone had no effect on fibronectin synthesis by cultured RPE cells. CONCLUSION: We conclude that the anti-fibrotic effect of pirfenidone may be partly mediated through inhibition of TGF-beta1-induced fibronectin synthesis.
PURPOSE:Pirfenidone is a novel anti-fibrotic drug that has been shown to inhibit fibroblast growth and collagen synthesis induced by transforming growth factor (TGF)-beta1. In the present study we investigated the ability of pirfenidone to moderate fibronectin synthesis by cultured human retinal pigment epithelial (RPE) cells maintained in media containing 1% foetal bovine serum when stimulated with TGF-beta1. METHODS: Primary human RPE cultures were used. Treatments included TGF-beta1, pirfenidone and pirfenidone with TGF-beta1. After 72 h treatments, cell growth was determined by cell counting and fibronectin was measured by ELISA. RESULTS:Transforming growth factor-beta1 (1-10 ng/mL) increased the production of soluble fibronectin, while pirfenidone (300 micromol/L) significantly reduced the TGF-beta1-induced synthesis of fibronectin. Pirfenidone alone had no effect on fibronectin synthesis by cultured RPE cells. CONCLUSION: We conclude that the anti-fibrotic effect of pirfenidone may be partly mediated through inhibition of TGF-beta1-induced fibronectin synthesis.
Authors: Brigitte C Widemann; Dusica Babovic-Vuksanovic; Eva Dombi; Pamela L Wolters; Stewart Goldman; Staci Martin; Anne Goodwin; Wendy Goodspeed; Mark W Kieran; Bruce Cohen; Susan M Blaney; Allison King; Jeffrey Solomon; Nicholas Patronas; Frank M Balis; Elizabeth Fox; Seth M Steinberg; Roger J Packer Journal: Pediatr Blood Cancer Date: 2014-04-22 Impact factor: 3.167
Authors: Paul Angulo; Robert L MacCarty; Pamela B Sylvestre; Roberta A Jorgensen; Russell H Wiesner; Nicholas A LaRusso; Keith D Lindor Journal: Dig Dis Sci Date: 2002-01 Impact factor: 3.199
Authors: Jacob D Estes; Cavan Reilly; Charles M Trubey; Courtney V Fletcher; Theodore J Cory; Michael Piatak; Samuel Russ; Jodi Anderson; Thomas G Reimann; Robert Star; Anthony Smith; Russell P Tracy; Anna Berglund; Thomas Schmidt; Vicky Coalter; Elena Chertova; Jeremy Smedley; Ashley T Haase; Jeffrey D Lifson; Timothy W Schacker Journal: J Infect Dis Date: 2014-09-22 Impact factor: 5.226
Authors: Dusica Babovic-Vuksanovic; Lydia Petrovic; Bruce E. Knudsen; Timothy B. Plummer; Joseph E. Parisi; Srdan Babovic; Jeffrey L. Platt Journal: J Biomed Biotechnol Date: 2004